Retatrutide

As the highest purity peptides option for triple-agonist metabolic research, retatrutide is a first-in-class triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors — the broadest metabolic research footprint of any current incretin-class compound. The peptide is engineered as a balanced triple agonist based on a glucagon-like peptide scaffold, with structural modifications that confer affinity for all three class B GPCRs while maintaining a prolonged pharmacokinetic profile through fatty acid chain-mediated albumin binding. At the GLP-1 receptor, retatrutide activates the canonical Galphas/cAMP/PKA insulinotropic cascade in pancreatic beta-cells with glucose dependency. At the GIP receptor, it provides complementary incretin signalling that amplifies insulin secretion and modulates adipose tissue metabolism. Critically, at the glucagon receptor (GCGR) — expressed primarily on hepatocytes — retatrutide activates signalling that stimulates hepatic glucose output and, more significantly for metabolic research, promotes lipolysis and fatty acid oxidation in adipose tissue and liver. The glucagon receptor arm distinguishes retatrutide from dual agonists: glucagon receptor activation is associated with increased energy expenditure, hepatic lipid metabolism, and weight reduction through pathways distinct from appetite suppression alone. The integrated triple-receptor signalling produces combined insulinotropic, appetite-suppressing, and lipolytic effects — the broadest metabolic pathway coverage in the incretin agonist class.